CLCA4: A prognostic marker and therapeutic enhancer for colorectal cancer
Peer-Reviewed Publication
This month, we’re focusing on infectious diseases, a topic that affects lives and communities around the world. Here, you’ll find the latest research news, insights, and discoveries shaping how infectious diseases are being studied, prevented, and treated globally.
Updates every hour. Last Updated: 20-Jun-2026 23:15 ET (21-Jun-2026 03:15 GMT/UTC)
Colorectal cancer (CRC) is one of the most prevalent and lethal malignancies globally, with long-term survival heavily hindered by tumor recurrence, metastasis, and therapy resistance driven by a subpopulation of cancer stem cells (CSCs). While immune checkpoint blockade has revolutionized cancer treatment, its efficacy as a monotherapy in CRC remains limited, largely due to CSC-mediated immune evasion and adaptive resistance.
An intestinal pathogen reshapes the gut environment to fuel its own colonization and cause diseases. A multi-institutional research team showed that enterotoxigenic Bacteroides fragilis (ETBF), which causes diarrhea and has been implicated in colitis (inflammation of the colon) and colorectal cancer, uses a toxin it produces to reprogram intestinal cell metabolism and generate conditions that support its growth. The study, published April 30 in the journal Cell, points to new therapeutic strategies for disrupting the growth of pathogens like ETBF.
Cases of several cancers are rising in England among both younger and older adults, but rates of bowel and ovarian cancer are rising only among younger adults (under 50s), finds research published in the open access journal BMJ Oncology. Some other types of cancer are also rising faster in younger adults than they are in older adults, the findings indicate. While excess weight is a key contributor, it’s unlikely to fully explain these patterns, say the researchers.
A study published in Science Bulletin identifies tRF-Glu-TTC-013, a tRNA-derived fragment, as a key driver of colorectal cancer liver metastasis. The researchers found that the molecule promotes tumour progression by enhancing glutamate metabolic reprogramming through a newly defined CREB3L1–AMDHD1 pathway.